M2 PHARMA-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
M2 EQUITYBITES-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
Global Banking News-September 4, 2019-Janssen Pharmaceutical wins FDA breakthrough therapy designation for investigational prophylactic vaccine for prevention of respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children worldwide (1-3); 2.7-3.8 million hospitalizations and 94,600-149,400 deaths occur each year among children <5 years of age as a result of RSV infection (4).
Respiratory syncytial virus (RSV)-positive laboratory detections have been reportable in Arizona since 2004 as part of the state's passive infectious disease surveillance.
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency has granted access to its PRIME, or PRIority MEdicines, scheme for MEDI8897, an extended half-life respiratory syncytial virus F monoclonal antibody being developed for the prevention of lower respiratory tract infection caused by RSV.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.